EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta

View source ↗

Summary

EMA recommends immediate suspension and recall of Zinbryta due to safety concerns, advising temporary withdrawal from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Zinbryta (daclizumab high yield process)